Verastem Oncology

Verastem Oncology logo

Verastem Oncology is a biopharmaceutical company focused on developing and commercializing medicines to improve the lives of patients with cancer. The company is headquartered in Needham, Massachusetts, United States.

History

Verastem Oncology was founded in 2010 by a group of scientists and entrepreneurs, including Robert Weinberg, a prominent cancer researcher. The company was established with the goal of developing therapies targeting cancer stem cells, which are believed to be responsible for tumor growth and recurrence.

In 2012, Verastem went public and was listed on the NASDAQ stock exchange under the ticker symbol VSTM. Over the years, the company has focused on developing treatments for various types of cancer, including leukemia, lymphoma, and solid tumors.

Research and Development

Verastem Oncology's research is centered on targeting cancer stem cells and the tumor microenvironment. The company has developed a pipeline of drug candidates that aim to disrupt the signaling pathways critical for cancer cell survival and proliferation.

One of the company's lead products is duvelisib, an oral dual inhibitor of PI3K-delta and PI3K-gamma, which has been approved for the treatment of certain types of blood cancers. Verastem is also exploring the potential of other compounds in its pipeline for the treatment of solid tumors.

Collaborations and Partnerships

Verastem Oncology has entered into several strategic collaborations and partnerships to advance its research and development efforts. These partnerships have included collaborations with academic institutions, research organizations, and other pharmaceutical companies to enhance the development of its drug candidates.

Market and Financials

As a publicly traded company, Verastem Oncology reports its financial performance on a quarterly basis. The company generates revenue primarily through the sale of its approved products and through licensing agreements with other companies.

Related pages

• Biopharmaceutical
• Cancer treatment
• Pharmaceutical industry